An ‘epic scientific misadventure’: NIH head Francis Collins ponders fallout from CRISPR baby study
By Jon Cohen,
Science
| 11. 30. 2018
“Should such epic scientific misadventures proceed, a technology with enormous promise for prevention and treatment of disease will be overshadowed by justifiable public outrage, fear, and disgust. NIH does not support the use of gene-editing technologies in human embryos.”
A “profoundly unfortunate,” “ill-considered,” “epic scientific misadventure” that “flout[ed] international ethical norms” and was “largely carried out in secret” with “utterly unconvincing” justifications. Those are the words in a statement issued by Francis Collins, head of the U.S. National Institutes of Health (NIH) in Bethesda, Maryland, in response to the claim by He Jiankui of the Southern University of Science and Technology in Shenzhen, China, that he used CRISPR to genetically modify two embryos, resulting in the recent birth of twin girls.
The scathing condemnation from the typically measured NIH chief, who has done landmark genetic research himself, came hours after He first described his work at the second International Summit on Human Genome Editing in Hong Kong, China, on Wednesday. “The need for development of binding international consensus on setting limits for this kind of research, now being debated in Hong Kong, has never been more apparent,” Collins wrote.
The next day, the meeting’s prominent organizing committee—convened by academies of science and medicine from the United States, the United Kingdom, and Hong Kong—issued its own statement about what it...
Related Articles
By Carl Zimmer, The New York Times | 10.20.2026
For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient.
Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly...
By Noah Fromson, HealthLab | 10.19.2026
Gene therapy is no longer the future of medicine — it’s reality. Treatments that replace, silence or edit genes are already changing clinical care.
There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets...
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...